Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implant vs Standardized Therapy

Inclusion Criteria: * Males and non-pregnant females at least 6 years of age * History of recurrent unilateral or asymmetric non-infectious posterior uveitis of at east 1 year duration not associated with significant systemic activity of the disease * The more severely affected eye having had at least 2 separate recurrences * The more severely affected eye having been treated by systemic therapy for at least one month just before inclusion * Visual acuity (VA) of at least 1.4 logMAR units at enrollment * At time of enrollment, \</=10 anterior chamber cells/HPF and vitrous haze\</= grade 2. Exclusion Criteria: * known allergy or contraindication to fluocinolone acetonide, systemic corticosteroids, or the immunosuppressive agents to be administered * history of retinal detachment, retinoschisis in the area of implantation, or media opacity precluding evaluation of the retina and vitreous * presence or history of uncontrolled IOP while on steroid therapy resulting in loss of vision, or IOP \>25 mm Hg requiring at least 2 types of antiglaucoma medication to be reduced to \<25 mm Hg * history of NIPU only or iritis only with no vitritis, macular edema, vitreous cells, or vitreous haze * infectious etiology, vitreous hemorrhage, or a toxoplasma scar in the study eye * ocular surgery and/or trauma on the study eye within 3 months prior to enrollment, or trabeculoplasty or yttrium aluminum garnet laser within 1 month prior to study enrollment * monocularity * AIDS * pregnancy/lactation * potential for noncompliance * or participation in other clinical studies within 1 month of enrollment.